Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kami Maddocks

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
Cancer Medicine|January 19, 2023
Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agentsMuhammad Salman Faisal, Walter Hanel, Timothy Voorhees, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 26, 2021
Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic MalignancyAshley E Rosko, Sarah Wall, Robert Baiocchi, et al.
American Journal of Hematology|February 3, 2015
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)Kami Maddocks, Lai Wei, Darlene Rozewski, et al.
Blood Advances|April 4, 2023
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphomaTycel J Phillips, David Bond, Radihka Takiar, et al.
Blood|July 9, 2014
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLLDalia El-Gamal, Katie Williams, Taylor D LaFollette, et al.
Blood|May 15, 2015
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activationTa-Ming Liu, Jennifer A Woyach, Yiming Zhong, et al.
British Journal of Haematology|July 1, 2025
Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphomaJohn Sharp, Qiuhong Zhao, Timothy J Voorhees, et al.
Blood|October 9, 2014
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cellsTa-Ming Liu, Yonghua Ling, Jennifer A Woyach, et al.
British Journal of Haematology|April 21, 2015
Jumping translocations, a novel finding in chronic lymphocytic leukaemiaCecelia R Miller, Deborah Stephens, Amy S Ruppert, et al.
American Journal of Hematology|July 24, 2015
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patientsDeborah M Stephens, Amy S Ruppert, William G Weirda, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Cancer Medicine|January 19, 2023
Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agentsMuhammad Salman Faisal, Walter Hanel, Timothy Voorhees, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 26, 2021
Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic MalignancyAshley E Rosko, Sarah Wall, Robert Baiocchi, et al.
American Journal of Hematology|February 3, 2015
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)Kami Maddocks, Lai Wei, Darlene Rozewski, et al.
Blood Advances|April 4, 2023
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphomaTycel J Phillips, David Bond, Radihka Takiar, et al.
Blood|July 9, 2014
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLLDalia El-Gamal, Katie Williams, Taylor D LaFollette, et al.
Blood|May 15, 2015
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activationTa-Ming Liu, Jennifer A Woyach, Yiming Zhong, et al.
British Journal of Haematology|July 1, 2025
Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphomaJohn Sharp, Qiuhong Zhao, Timothy J Voorhees, et al.
Blood|October 9, 2014
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cellsTa-Ming Liu, Yonghua Ling, Jennifer A Woyach, et al.
British Journal of Haematology|April 21, 2015
Jumping translocations, a novel finding in chronic lymphocytic leukaemiaCecelia R Miller, Deborah Stephens, Amy S Ruppert, et al.
American Journal of Hematology|July 24, 2015
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patientsDeborah M Stephens, Amy S Ruppert, William G Weirda, et al.
Pageof 10